JP2007509063A - Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 - Google Patents
Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 Download PDFInfo
- Publication number
- JP2007509063A JP2007509063A JP2006535420A JP2006535420A JP2007509063A JP 2007509063 A JP2007509063 A JP 2007509063A JP 2006535420 A JP2006535420 A JP 2006535420A JP 2006535420 A JP2006535420 A JP 2006535420A JP 2007509063 A JP2007509063 A JP 2007509063A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mbp
- cell
- vaccine
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 32
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title description 20
- 230000005867 T cell response Effects 0.000 title description 5
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims abstract description 88
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 144
- 101710107068 Myelin basic protein Proteins 0.000 claims description 75
- 102000047918 Myelin Basic Human genes 0.000 claims description 74
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 229940030156 cell vaccine Drugs 0.000 claims description 9
- 210000004248 oligodendroglia Anatomy 0.000 claims description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims description 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims description 3
- 239000003226 mitogen Substances 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 2
- 102000016202 Proteolipids Human genes 0.000 claims description 2
- 108010010974 Proteolipids Proteins 0.000 claims description 2
- 235000013395 American pokeweed Nutrition 0.000 claims 1
- 108010062580 Concanavalin A Proteins 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 102000055324 Myelin Proteolipid Human genes 0.000 claims 1
- 108700021862 Myelin Proteolipid Proteins 0.000 claims 1
- 240000007643 Phytolacca americana Species 0.000 claims 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 claims 1
- 230000001885 phytohemagglutinin Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 59
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract description 20
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract description 18
- 239000012634 fragment Substances 0.000 abstract description 13
- 108010013476 HLA-A24 Antigen Proteins 0.000 abstract description 9
- 230000002163 immunogen Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 2
- 230000003053 immunization Effects 0.000 abstract 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 113
- 108090000765 processed proteins & peptides Proteins 0.000 description 72
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 230000003013 cytotoxicity Effects 0.000 description 17
- 231100000135 cytotoxicity Toxicity 0.000 description 17
- 230000001472 cytotoxic effect Effects 0.000 description 16
- 108091054437 MHC class I family Proteins 0.000 description 12
- 231100000433 cytotoxic Toxicity 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 102000006386 Myelin Proteins Human genes 0.000 description 9
- 108010083674 Myelin Proteins Proteins 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 208000016192 Demyelinating disease Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 206010012305 Demyelination Diseases 0.000 description 7
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 201000002491 encephalomyelitis Diseases 0.000 description 7
- 210000005012 myelin Anatomy 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000054064 human MBP Human genes 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101100400614 Homo sapiens MBP gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/453—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51221203P | 2003-10-17 | 2003-10-17 | |
| PCT/US2004/034448 WO2005037309A1 (en) | 2003-10-17 | 2004-10-18 | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509063A true JP2007509063A (ja) | 2007-04-12 |
| JP2007509063A5 JP2007509063A5 (cg-RX-API-DMAC7.html) | 2007-11-29 |
Family
ID=34465326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535420A Pending JP2007509063A (ja) | 2003-10-17 | 2004-10-18 | Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20080107664A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1677821B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007509063A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1893971A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004281817B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0415519A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2542668C (cg-RX-API-DMAC7.html) |
| IL (1) | IL174935A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ546552A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005037309A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509063A (ja) * | 2003-10-17 | 2007-04-12 | ベイラー カレッジ オブ メディスン | Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 |
| ES2553192T3 (es) * | 2006-05-05 | 2015-12-04 | Opexa Therapeutics | Vacuna de células T |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| US9125850B2 (en) * | 2009-11-14 | 2015-09-08 | Cardio Vax, Llc | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
| RU2435556C1 (ru) * | 2010-04-23 | 2011-12-10 | Владимир Васильевич Лантух | Способ лечения дистрофических заболеваний заднего полюса глаза |
| WO2013063713A1 (zh) * | 2011-10-31 | 2013-05-10 | 鑫品生医科技股份有限公司 | 诱发产生综合免疫细胞的方法 |
| CN105085615A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种多肽序列及其应用 |
| CN105085616A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种氨基酸序列及其应用 |
| KR20190124214A (ko) * | 2017-01-20 | 2019-11-04 | 아타라 바이오테라퓨틱스 인크. | 자가 t 세포를 사용하여 다발성 경화증을 치료하는 방법 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08500083A (ja) | 1992-04-09 | 1996-01-09 | オートイミューン インク | ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制 |
| JP2002513008A (ja) | 1998-04-29 | 2002-05-08 | ジョージタウン ユニヴァーシティー | Ｈｌａ−作動薬及び拮抗薬としてのｈｌａ結合性化合物の同定及び使用方法 |
| WO2003024393A2 (en) * | 2001-09-14 | 2003-03-27 | Opexa Pharmaceuticals, Inc. | Autologous t-cell vaccines materials and method |
| WO2003082919A2 (en) | 2002-04-03 | 2003-10-09 | Applied Research Systems Ars Holding N.V. | Ox40r binding agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| PT1407004E (pt) * | 2001-05-15 | 2009-08-31 | Ortho Mcneil Janssen Pharm | Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas |
| JP2007509063A (ja) * | 2003-10-17 | 2007-04-12 | ベイラー カレッジ オブ メディスン | Ｃｄ８＋細胞傷害性ｔ細胞応答を増大させる方法、および多発性硬化症を処置するための方法 |
-
2004
- 2004-10-18 JP JP2006535420A patent/JP2007509063A/ja active Pending
- 2004-10-18 WO PCT/US2004/034448 patent/WO2005037309A1/en not_active Ceased
- 2004-10-18 BR BRPI0415519-0A patent/BRPI0415519A/pt not_active Application Discontinuation
- 2004-10-18 US US10/575,831 patent/US20080107664A1/en not_active Abandoned
- 2004-10-18 EP EP04795590A patent/EP1677821B1/en not_active Expired - Lifetime
- 2004-10-18 CN CNA2004800372329A patent/CN1893971A/zh active Pending
- 2004-10-18 CA CA2542668A patent/CA2542668C/en not_active Expired - Fee Related
- 2004-10-18 NZ NZ546552A patent/NZ546552A/en not_active IP Right Cessation
- 2004-10-18 AU AU2004281817A patent/AU2004281817B2/en not_active Ceased
-
2006
- 2006-04-11 IL IL174935A patent/IL174935A/en not_active IP Right Cessation
-
2009
- 2009-12-03 US US12/630,228 patent/US20100183546A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08500083A (ja) | 1992-04-09 | 1996-01-09 | オートイミューン インク | ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制 |
| JP2002513008A (ja) | 1998-04-29 | 2002-05-08 | ジョージタウン ユニヴァーシティー | Ｈｌａ−作動薬及び拮抗薬としてのｈｌａ結合性化合物の同定及び使用方法 |
| WO2003024393A2 (en) * | 2001-09-14 | 2003-03-27 | Opexa Pharmaceuticals, Inc. | Autologous t-cell vaccines materials and method |
| WO2003082919A2 (en) | 2002-04-03 | 2003-10-09 | Applied Research Systems Ars Holding N.V. | Ox40r binding agents |
Non-Patent Citations (9)
| Title |
|---|
| CSNC200900857005; 医学のあゆみ Ｖｏｌ．２０６, 200309, ｐｐ．８４５-８ * |
| JPN5006017004; ＳＴＥＩＮＭＡＮ ＬＥＷＲＥＮＣＥ: ＪＯＵＲＮＡＬ ＯＦ ＥＸＰＥＲＩＭＥＮＴＡＬ ＭＥＤＩＣＩＮＥ Ｖ１９４ Ｎ５, 20010903, Ｐ． Ｆ２７-Ｆ３０ |
| JPN5006017005; ＨＵＳＥＢＹ ＥＲＩＣ Ｓ: ＪＯＵＲＮＡＬ ＯＦ ＥＸＰＥＲＩＭＥＮＴＡＬ ＭＥＤＩＣＩＮＥ Ｖ１９４ Ｎ５, 20010903, Ｐ６６９-６７６ |
| JPN5006017006; ＳＵＮ Ｄ: ＪＯＵＲＮＡＬ ＯＦ ＩＭＭＵＮＯＬＯＧＹ Ｖ１６６ Ｎ１２, 20010615, Ｐ７５７９-７５８７ |
| JPN5006017007; ＴＳＵＣＨＩＤＡ Ｔ: ＰＲＯＣＥＥＤＩＮＧＳ ＯＦ ＴＨＥ ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥＳ ＯＦ ＵＳＡ Ｖ９１ Ｎ２３, 199411, Ｐ１０８５９-１０８６３, ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥ |
| JPN5006017009; ＳＴＩＮＩＳＳＥＮ Ｐ: ＣＲＩＴＩＣＡＬ ＲＥＶＩＥＷＳ ＩＮ ＩＭＭＵＮＯＬＯＧＹ Ｖ１７ Ｎ１, 1997, Ｐ３３-７５ |
| JPN6010055451; Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ Ｖｏｌ．９８, 2001, ｐｐ．６３０１-６ * |
| JPN6012003714; Ｉｍｍｕｎｉｔｙ Ｖｏｌ．２, 1995, ｐｐ．１８５-９４ |
| JPN6012003715; 医学のあゆみ Ｖｏｌ．２０６, 200309, ｐｐ．８４５-８ |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004281817A1 (en) | 2005-04-28 |
| BRPI0415519A (pt) | 2006-12-26 |
| US20100183546A1 (en) | 2010-07-22 |
| EP1677821B1 (en) | 2013-02-27 |
| IL174935A (en) | 2012-01-31 |
| AU2004281817B2 (en) | 2010-07-22 |
| NZ546552A (en) | 2009-10-30 |
| CN1893971A (zh) | 2007-01-10 |
| CA2542668A1 (en) | 2005-04-28 |
| US20080107664A1 (en) | 2008-05-08 |
| EP1677821A1 (en) | 2006-07-12 |
| CA2542668C (en) | 2014-04-29 |
| IL174935A0 (en) | 2006-08-20 |
| WO2005037309A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zang et al. | Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis | |
| US8053235B2 (en) | Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use | |
| Lindert et al. | Multiple sclerosis: B-and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein | |
| Roberts et al. | Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells | |
| AU2008201685B2 (en) | CD4+CD25+ regulatory T cells from human blood | |
| US20100183546A1 (en) | Method for Increasing CD8+ Cytotoxic T Cell Responses and for Treating Multiple Sclerosis | |
| Kil et al. | T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis | |
| JP2004512030A (ja) | 特異的細胞溶解性ｔ細胞応答を誘導するための組成物および方法 | |
| Salvetti et al. | T-lymphocyte reactivity to the recombinant mycobacterial 65-and 70-kDa heat shock proteins in multiple sclerosis | |
| JP2015017129A (ja) | 自己ｔ細胞ワクチン材料および方法 | |
| JP5776684B2 (ja) | 促進された共培養樹状細胞を使用して抗原特異的ｔ細胞応答を刺激するための方法 | |
| Birnbaum et al. | Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens | |
| KR20210041559A (ko) | 다발경화증에서의 면역우세 단백질 및 단편 | |
| Venken et al. | Memory CD4+ CD127high T cells from patients with multiple sclerosis produce IL-17 in response to myelin antigens | |
| AU2007247869B2 (en) | T-cell vaccine | |
| WO2013076181A1 (en) | Methods of enrichment and isolation of regulatory t-cells and use of the same | |
| WO2008028229A1 (en) | Methods of identifying markers | |
| Ghezzi | UNRAVELLING THE ROLE OF MUCOSAL ASSOCIATED INVARIANT T CELLS IN THE PATHOGENESIS OF MULTIPLE SCLEROSIS AND ITS ANIMAL MODEL | |
| Ihantola | T-cell dysfunction and autoantigen recognition in type 1 diabetes | |
| AU2022319971A1 (en) | Selective tolerization - methods of selectively generating tolerogenic dendritic cells | |
| HK1102914A (en) | A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis | |
| AU2011203204A1 (en) | CD4+CD25+ regulatory T cells from human blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071015 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071015 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111118 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111212 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120127 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131008 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131011 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131113 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131206 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140714 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140718 |